The objective of the present study was to examine the impact of preeclampsia on the relation of leptin and neuropeptide Y (NPY) gene expression in human placenta. A second goal was to monitor the change of leptin messenger RNA (mRNA) with increasing gestational age.
0.03). NPY/␤-actin mRNA was significantly reduced in the preeclampsia group (0.003 Ϯ 0.001 vs. 0.026 Ϯ 0.008 RU in controls; P ϭ 0.01). The NPY/leptin ratio was 0.11 Ϯ 0.09 for preeclamptic placenta samples and 1.7 Ϯ 0.6 RU for the controls (P ϭ 0.02). The leptin/␤-actin ratio was significantly lower in placenta from premature deliveries than in term deliveries (0.02 Ϯ 0.004 vs. 0.12 Ϯ 0.05 RU; P ϭ 0.01). Similar results were obtained for normalization to glyceraldehyde-3-phosphate dehydrogenase mRNA.
Our data suggest an increase of placental leptin production with gestational age. In patients with preeclampsia, elevated leptin expression goes along with suppressed NPY expression. This resembles hypothalamic regulation. (J Clin Endocrinol Metab 84: [2755] [2756] [2757] [2758] 1999) T HE HUMAN placenta has been shown to be a source of leptin. It has become clear recently that leptin is produced and secreted from placental trophoblast cells into the maternal circulation in considerable amounts (1, 2) . In this respect, human beings differ from rodents, where placental leptin production does not substantially contribute to leptin plasma levels (3) . Patients with preeclampsia show elevated plasma concentrations of leptin. In placental tissue specimens from women with preeclampsia, there is an increased leptin expression, when compared with age-matched controls (4) . The presence of the leptin receptor in placental tissue has been demonstrated shortly after its discovery, making the placenta a possible site for leptin action (5) .
In the hypothalamus of mice, leptin suppresses the expression of neuropeptide Y (NPY) that is well known to raise food intake in these animals (6) . In humans, however, there is no clear evidence that leptin interacts with NPY secretion. In the cerebrospinal fluid of adipose and lean subjects, no relation between leptin and NPY levels is found. This may either be attributed to a lack of interaction between leptin and NPY in man or a mechanism that is restricted to limited portions of the brain and does not influence concentrations in the cerebrospinal fluid (7) .
The objective of the present study was to examine the relation of leptin and NPY expression in placental tissue from patients with preeclampsia, in comparison with controls. A second goal was to investigate whether the placental expression of leptin and NPY shows a maturation with the progression of pregnancy.
Subjects and Methods Patients
Placental tissue was obtained in collaboration with the Department of Gynecology and Obstetrics at the University of Giessen. The study was approved by the ethics committee of the University of Giessen. Placental tissue was obtained at the time of vaginal delivery or cesarean section from three different parts of the placenta after removal of the amnionic membrane and maternal decidua. Placental tissue from 18 healthy women with normal pregnancy (age, 24 -36 yr; at 37-42 weeks of gestation) was compared with placenta from 17 patients giving birth to premature infants after premature labor (27-33 weeks of gestation; age, 15-41 yr) and to tissue from 11 patients with preeclampsia (age, 22-37; at 27-41 weeks of gestation). Preeclampsia was diagnosed according to international criteria (8) . Because of the limited number of patients, no distinction between mild and severe preeclampsia was made. Patient characteristics are shown in Table 1 .
TaqMan real-time PCR
RNA was extracted using a commercial kit (RNAzol-B isolation kit, WAK-Chemie Medical GmbH, Bad Homburg, Germany). To monitor gene expression, we used quantitative real-time RT-PCR analysis. This novel approach makes use of the 5Ј exonuclease activity of the DNA polymerase (AmpliTaq Gold). Briefly, within the amplicon defined by a gene-specific PCR primer pair, a oligonucleotide probe, labeled with two fluorescent dyes, is created (designated as TaqMan probe). As long as the probe is intact, the emission of the reporter dye (i.e. 6-carboxyfluorescein, FAM) at the 5Ј-end is quenched by the second fluorescence dye (6-carboxytetramethylrhodamine, TAMRA) at the 3Ј-end. During the extension phase of a PCR, the polymerase cleaves the TaqMan probe, resulting in a release of reporter dye. The increasing amount of reporter dye emission is detected by an automated sequence detector combined with a special software (ABI Prism 7700 Sequence Detection System, Perkin-Elmer Corp., Foster City, CA). The algorithm normalizes the reporter signal to a passive reference. Next, the algorithm multiplies the sd of the background reporter signal in the first few cycles (in most PCR systems, cycles 3-15, respectively) by a default factor of 10, to determine a threshold. The cycle at which this baseline level is exceeded is defined as threshold cycle (CT). CT depends on the initial template copy number and on the efficiency of both the DNA amplification and the cleavage of the TaqMan probe. The CT values of the samples are interpolated to an external reference curve constructed by plotting the relative or absolute amounts of a serial dilution of a known template vs. the corresponding CT values.
Commercial reagents (TaqMan PCR Reagent Kit, Perkin-Elmer Corp.) and conditions were applied according to the manufacturer's protocol. A total of 2.5 L of complementary DNA (reverse transcription mixture) and oligonucleotides at a final concentration of 300 nmol/L of primers and 200 nmol/L of TaqMan hybridization probe were analyzed in a 25-L vol. The oligonucleotides of each target of interest were designed by the Primer Express software (Perkin-Elmer Corp.) using uniform selection parameters that allow the application of standard cycle conditions.
Leptin and NPY gene expression was related to the housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ␤-actin. In addition, for NPY, the neuronal marker protein gene product 9.5 (PGP9.5) was used to normalize messenger RNA (mRNA) concentration.
The following primers and TaqMan probes were used: The thermocycler parameters were 50 C for 2 min (for carry-over prevention with Uracil-N-glycosylase), 95 C for 10 min (for hot start PCR), followed by 40 cycles of 95 C for 15 sec and 60 C for 1 min.
Statistical analysis
All values are expressed as mean Ϯ sem. Values were compared using Student's t test for parametric data. A P value of less than 0.05 was considered significant.
Results
The placental tissue of patients with preeclampsia showed a significantly higher leptin mRNA expression than the gestational age-matched controls, irrespective of the housekeeping gene (Table 2a ). In contrast, NPY mRNA content in the placental tissue of mothers with preeclampsia was significantly lower than in the controls (Table 2a ). The NPY/leptin mRNA ratio was 15-to 20-fold lower in the preeclampsia group than in the control group (Fig. 1) .
In placental tissue of mothers giving birth to premature infants, there was a significantly lower leptin gene expression than in term placentas (Fig. 2) . This difference was prevalent, irrespective of the housekeeping gene used for the normalization of leptin mRNA (Table 2b ). There was no difference in NPY gene expression between placental tissue from women delivering term and premature neonates (Table  2b) . However, higher NPY gene expression levels were only reached in the advanced stages of gestation (Fig. 3) .
There was no relation between leptin gene expression and the newborns' weight percentile (r 2 ϭ 0.006, P ϭ 0.62). Similarly, there was no correlation between leptin/␤-actin mRNA expression and the placental weight for all patients studied (r 2 ϭ 0.001, P ϭ 0.82). More specifically, leptin/␤- Significant differences for preterm from term group and preeclampsia from preeclampsia control group are symbolized by asterisks. *, Ͻ0.05; **, Ͻ0.01; ***, Ͻ0.001; NS, not significant; BMI, body mass index.
actin gene expression did not correlate with the placental weight in the term, preeclampsia, and preeclampsia control groups (r 2 ϭ 0.03, P ϭ 0.52; r 2 ϭ 0.16, P ϭ 0.28; and r 2 ϭ 0.1, P ϭ 0.34, respectively). Similar results were seen for normalization to GAPDH gene expression.
No relation was seen between maternal systolic and diastolic blood pressure in the preeclampsia group and the placental leptin/␤-actin mRNA expression (r 2 ϭ 0.005, P ϭ 0.83; and r 2 ϭ 0.004, P ϭ 0.85, respectively). Similar results were seen for normalization to GAPDH gene expression.
Discussion
The present study elicits a reduced NPY mRNA content in human placental tissue of patients with preeclampsia, whereas leptin gene expression is augmented. These results may indicate a paracrine suppressive effect of leptin on NPY expression in human placenta. This observation shows similarities to the regulation of NPY mRNA expression in the hypothalamus of mice (6) . In both tissues, high leptin expression is associated with low NPY expression. It is of interest that hypoxia increases leptin production in human choriocarcinoma cells (4) . Consequently, hypoxia might decrease NPY production in placenta via an increase of leptin. Because NPY is a potent vasoconstrictor via the NPY Y1 receptor (7), it may be speculated that the leptin-NPY mechanism counteracts the vasoconstriction associated with preeclamptic changes in the placenta. Alternatively, NPY may induce trophic changes in placental tissue via the NPY Y1 or NPY Y5 receptor (9, 10) . It seems rather unlikely, however, that placental NPY production affects the NPY concentrations in the fetal or maternal circulation. Results from our group suggest that the increasing umbilical cord NPY plasma concentrations immediately after spontaneous delivery are caused by an increase in the NPY release from neonatal tissue. NPY plasma concentrations in the mothers do not change during pregnancy, making a substantial placental contribution to maternal NPY levels improbable (11) .
We have no evidence that the placental leptin expression is associated with placental or neonatal weight. Consequently, as results from our group suggest, the relation between birth weight and serum leptin levels in umbilical cord blood (12) seems to be attributable to neonatal leptin production rather than to a placental derivation of the protein (13) . These observations underline the concept of paracrine leptin effects in the placenta.
The comparison of leptin expression in placental tissue of premature and term deliveries suggests an effect of gestational age on the maturation of placental leptin production during ontogeny. This may suggest that leptin production in the placenta becomes more important during the last trimester of gestation. Alternatively, the increasing leptin mRNA might be a consequence of the declining placental perfusion and a subsequent increase in hypoxic compartments of the organ (4) . Cell culture studies with placental trophoblast cells will have to show the exact pathomechanism of leptin action on the NPY mRNA expression in human placenta. These studies may also help to elucidated the signal transduction pathways that are involved in the interaction of these two systems.
There is a lack of change of placental NPY mRNA expression during gestational maturation. This might be caused by an immaturity of the leptin action on NPY gene expression, for instance, as a consequence of underdeveloped leptin receptor function. However, there is a certain tendency to There is no relation between gestational age and NPY gene expression (r 2 ϭ 0.04, P ϭ 0.25). Similar results were seen for normalization to GAPDH and PGP9.5 gene expression.
higher NPY expression in the later stages of gestation, suggesting that only the mature placenta is able to produce greater amounts of NPY mRNA.
In summary, our data suggest that the possible role of placental leptin becomes most important towards the end of gestation. One mechanism of leptin action in the placenta may be the suppression of NPY. In this respect, it resembles hypothalamic regulation.
